These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 17212195)

  • 1. [Antiatherosclerotic effects of antihypertensive drugs].
    Galesić K
    Lijec Vjesn; 2006; 128(11-12):341-5. PubMed ID: 17212195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathogenesis of atherosclerosis and its complications: effects of antihypertensive drugs.
    Spence JD
    J Hum Hypertens; 1989 Dec; 3 Suppl 2():63-8. PubMed ID: 2691695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of antihypertensive drugs on atherogenic factors: possible importance of drug selection in prevention of atherosclerosis.
    Spence JD
    J Cardiovasc Pharmacol; 1985; 7 Suppl 2():S121-5. PubMed ID: 2409360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenetic interactions of three candidate gene polymorphisms with ACE-inhibitors or beta-blockers and the risk of atherosclerosis.
    Schelleman H; Klungel OH; Witteman JC; Hofman A; van Duijn CM; de Boer A; Stricker BH
    Br J Clin Pharmacol; 2007 Jul; 64(1):57-66. PubMed ID: 17298481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Arterial hypertension in patients on long-term haemodialysis].
    Pavlović D; Heinrich B; Germin-Petrović D; Pavlović N
    Lijec Vjesn; 2006; 128(11-12):381-4. PubMed ID: 17212202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antihypertensive treatment and regression of atherosclerosis.
    Correia JF
    Rev Port Cardiol; 1992; 11(7-8):623-30. PubMed ID: 1389300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antihypertensive drugs and the sympathetic nervous system.
    Del Colle S; Morello F; Rabbia F; Milan A; Naso D; Puglisi E; Mulatero P; Veglio F
    J Cardiovasc Pharmacol; 2007 Nov; 50(5):487-96. PubMed ID: 18030057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 'Beyond blood pressure' means multiple risk factor intervention, not pleiotropic antihypertensive drugs.
    Staessen JA; Thijs L; Li Y; Kuznetsova T; Richart T; Wang J; Birkenhäger WH
    Curr Opin Cardiol; 2007 Jul; 22(4):335-43. PubMed ID: 17556887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of microalbuminuria in achieving blood pressure goals.
    Duka I; Bakris G
    Curr Opin Nephrol Hypertens; 2008 Sep; 17(5):457-63. PubMed ID: 18695385
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discordant effects of beta-blockade on central aortic systolic and brachial systolic blood pressure: considerations beyond the cuff.
    Epstein BJ; Anderson S
    Pharmacotherapy; 2007 Sep; 27(9):1322-33. PubMed ID: 17723086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic implications of recent megatrials in hypertension: in favor of new drugs.
    Volpe M; Tocci G
    J Nephrol; 2007; 20 Suppl 12():S12-8. PubMed ID: 18050137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular disease in dialysis patients: do some antihypertensive drugs have specific antioxidant effects or is it just blood pressure reduction? Does antioxidant treatment reduce the risk for cardiovascular disease?
    Aslam S
    Curr Opin Nephrol Hypertens; 2008 Jan; 17(1):99-105. PubMed ID: 18090678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of antihypertensive drug treatment on the risk of dementia and cognitive impairment.
    Poon IO
    Pharmacotherapy; 2008 Mar; 28(3):366-75. PubMed ID: 18294116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Does the rennin inhibitor aliskiren offer promising novel opportunities in the treatment of cardiovascular diseases?].
    Horký K
    Vnitr Lek; 2007 Apr; 53(4):364-70. PubMed ID: 17578167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nebivolol: a third-generation beta-blocker for hypertension.
    Cheng JW
    Clin Ther; 2009 Mar; 31(3):447-62. PubMed ID: 19393838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Usefulness of the alpha1-blocker doxazosin as a third-line antihypertensive drug.
    Ohta Y; Tsuchihashi T; Onaka U; Eto K; Ueno M
    Hypertens Res; 2007 Apr; 30(4):301-6. PubMed ID: 17541208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of hypertension by general practitioners and antihypertensive drugs expenditure in an urban environment.
    Marković BB; Kranjcević K; Stojanović-Spehar S; Blazeković-Milaković S; Kern J; Botica MV; Jelinić JD; Marković M
    Coll Antropol; 2009 Mar; 33(1):71-6. PubMed ID: 19408606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of dementia by antihypertensive drugs: how AT1-receptor-blockers and dihydropyridines better prevent dementia in hypertensive patients than thiazides and ACE-inhibitors.
    Fournier A; Oprisiu-Fournier R; Serot JM; Godefroy O; Achard JM; Faure S; Mazouz H; Temmar M; Albu A; Bordet R; Hanon O; Gueyffier F; Wang J; Black S; Sato N
    Expert Rev Neurother; 2009 Sep; 9(9):1413-31. PubMed ID: 19769454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antihypertensive treatment and stroke prevention in patients with and without chronic kidney disease: a review of controlled trials.
    Segall L; Oprisiu R; Fournier A; Covic A
    J Nephrol; 2008; 21(3):374-83. PubMed ID: 18587726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ACE inhibitor-based treatment and antihypertensive effects in patients with type 2 diabetes.
    Jarmuzewska EA; Rocchi R; Guidoni A; Mangoni AA
    Panminerva Med; 2008 Sep; 50(3):207-16. PubMed ID: 18927524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.